The trajectory of Viagra presents a intricate picture for shareholders. While the initial introduction generated massive profits, the lapse of its patent opened the door to off-brand versions, dramatically diminishing revenue. This presents a unique challenge for drug manufacturers relying on related blockbuster medications, suggesting that a carel

The legacy of Viagra, and its parent company copyright, presents a complex case study for investors. At first a blockbuster drug, producing billions in income, its patent expiration created a flood of knock-off medications, significantly diminishing its market share . While specific firms may try to capitalize on similar conditions , the present la